Should You Buy the Dip on This Top Growth Stock?

The biotech needs to overcome an issue most drugmakers face at some point.Biotech giant Regeneron Pharmaceuticals (REGN -0.17%) has performed pretty well this year and over the trailing-12-month period, thanks to solid financial results and exciting clinical and regulatory progress.However, the company has encountered some headwinds with one of its most important medicines, Eylea, which treats an eye disease called wet age-related macular degeneration (AMD). And recently, Regeneron got more bad news on the ...